Loading...

MLYS MINERALYS THERAPEUTICS INC US FDA Inspections 8-K Filing

MNRL

MLYS

MINERALYS THERAPEUTICS INC

(MLYS)

2025 8-K

Financial Results Announcement

FDA NDA Acceptance

Corporate Update

Financial Update

Stock Offering Details

Termination Notice

Product Expansion

Financial Statements

Financial Results

Trial Enrollment Complete

Financial Results

Trial Enrollment Complete

Trial Enrollment Complete

Financial Results

Appointment and Resignation

Clinical Trials Update

Earnings Report

Departure of Directors

Equity Offering

Private Placement

Appointment of Chief Busine...

Announcement of Launch-HTN ...

Data Presentation

Financial Results Announcement

Resignation and Appointments

Financial Results Announcement

Expansion of Phase 2 Trial

Earnings Report

Departure of Directors or C...

Financial Results Announcement

Amended Certificate and Bylaws

External Links:

Mineralys Therapeutics announced that the FDA has approved its IND application for a Phase 2 clinical trial of lorundrostat to treat moderate-to-severe obstructive sleep apnea and hypertension, with plans to start the trial in Q1 2025. The company believes it has enough funds to support its operations and clinical studies through Q1 2026.

AI Assistant

MINERALYS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.